19. Agricultural Biotechnology Part V. Renewable Energy and the Future of Humanity. NQ – Video

Posted on by


19. Agricultural Biotechnology Part V. Renewable Energy and the Future of Humanity. NQ
What is the carrying capacity of the planet? How many people can we put here until there is a Tragedy of the Commons? Oil and fossils fuels took millions of years to make and are a finite resource that we are burning at an alarming rate and probably contributing to global climate change. What are the possible solutions for the future that are renewable and sustainable?From:Albert KauschViews:0 0ratingsTime:01:27:12More inScience Technology

Originally posted here:
19. Agricultural Biotechnology Part V. Renewable Energy and the Future of Humanity. NQ - Video

27 . Medical Biotechnology: Part II. Gene Therapy, Tissue Engineering and Nanotechnology – Video

Posted on by


27 . Medical Biotechnology: Part II. Gene Therapy, Tissue Engineering and Nanotechnology
In theory, gene therapy offers a straight forward to the molecular treatment of various diseases, by using genes to prevent or treat disease by: Replacing a mutated gene(s) with a healthy copy; Inactivating/knocking out a mutated gene; or, Introducing new gene. Gene Therapy offers an approach to treating disease by either modifying the expressions of an individual #39;s genes or correction of abnormal genes. While this seems straight forward (ie replace or supply a healthy insulin gene in pancreatic cells of a diabetic) it has been difficult to actualize. Think here also about dual use problems (ie genetic doping for athletes, genetic modification enhancement for military personnel, and germline genetic engineering of humans with heritable genes). in this section we also review tissue engineering and some of the possibilities for nanotechnologies in medical devices. Nanosized GPS capable computers in our bloodstream?From:Albert KauschViews:0 0ratingsTime:36:53More inScience Technology

Read more from the original source:
27 . Medical Biotechnology: Part II. Gene Therapy, Tissue Engineering and Nanotechnology - Video

21. Pharmaceutical Biotechnology: Part Ib Emergent Technologies DNA-based Biotechnology NQ – Video

Posted on by


21. Pharmaceutical Biotechnology: Part Ib Emergent Technologies DNA-based Biotechnology NQ
With Recombinant DNA Drug development pharmaceutical biotechnology embraces the tools of genetic modification for new therapies. Similar to the technology introduced in the Agricultural Biotechnology section of this course, gene constructs can be made using DNA from different sources to make high value proteins that can be produced as injectable drugs. Insulin was one of the first recombinant DNA drugs to be made this way. Notice that recombinant insulin does not draw nearly the controversy as genetically modified tomatoes (even though they use the same technology). in this part we also examine the use of this technology for antibody based drugs and new vaccines.From:Albert KauschViews:0 0ratingsTime:58:56More inScience Technology

More here:
21. Pharmaceutical Biotechnology: Part Ib Emergent Technologies DNA-based Biotechnology NQ - Video

26. Medical Biotechnology: Part Ic. Animal and Human Cloning and Genetic Engineering NQ – Video

Posted on by


26. Medical Biotechnology: Part Ic. Animal and Human Cloning and Genetic Engineering NQ
Some of the same techniques described for stem cell research, have been extended and applied to animal cloning, creating part of the controversies surrounding both topics. What is cloning? Cloning an organism (as a totally different process distinguished from cloning a gene) is a process whereby all members are directly descended, asexually, from a single organism by......various ways, as we show in this section, and this demonstrates that all the information required for an organism and its development are in the a single cell. many animals have now been cloned, including, sheep (Dolly), cattle, pigs, mice, rats, fish, dogs, cats, horses, mules, and more recently monkeys. Can humans be cloned? Probably.From:Albert KauschViews:0 0ratingsTime:25:37More inScience Technology

See original here:
26. Medical Biotechnology: Part Ic. Animal and Human Cloning and Genetic Engineering NQ - Video

29. Medical Biotechnology:Biotechnology Applications in Tough Times. Part IIIb. Bioweapons NQ – Video

Posted on by


29. Medical Biotechnology:Biotechnology Applications in Tough Times. Part IIIb. Bioweapons NQ
Bioterrorism is the deliberate use of microbial agents and toxins as weapons. prior to 9/11 bioweapons were not considered a (very) serious threat, but now we realize the insidious possibility of human suicide delivery agents. Infected humans could act as dispersal genets for diseases that would otherwise be difficult to weaponize. In addition the applications of biotechnology and synthetic biology make these types of weapons cheaper and faster to manufacture that atomic weapons. This lecture review the top six most probable bioweapons and some of the possibilities for synthetic weapons in the future.From:Albert KauschViews:0 0ratingsTime:01:15:36More inScience Technology

The rest is here:
29. Medical Biotechnology:Biotechnology Applications in Tough Times. Part IIIb. Bioweapons NQ - Video

28 . Medical Biotechnology:Biotechnology Applications in Tough Times. Part IIIa. Pandemic Flu NQ – Video

Posted on by


28 . Medical Biotechnology:Biotechnology Applications in Tough Times. Part IIIa. Pandemic Flu NQ
An influenza pandemic is a global outbreak of disease that occurs when a new influenza A virus appears or "emerges" in the human population, causes serious illness, and then spreads easily from person to person worldwide. Is a worldwide outbreak of influenza possible? Probable is what experts would call it. Is the film Contagion science fiction? or a documentary on something that hasn #39;t happened yet? How accurate is it? How worried should we be? This lecture looks at a pandemic as a matter of time and puts current research into a biotechnology perspective.From:Albert KauschViews:0 0ratingsTime:01:10:53More inScience Technology

Read more here:
28 . Medical Biotechnology:Biotechnology Applications in Tough Times. Part IIIa. Pandemic Flu NQ - Video

Neuroscience to Neuro-patient: Melissa’s Chiari

Posted on by


Neuroscience to Neuro-patient: Melissa #39;s Chiari Pseudotumor Story
Just over a year ago my life came to a screeching halt because I woke up with a headache. I had been (self) diagnosed with Chiari Malformation in 2008 and had successful decompression surgery in 2009. Two years later I was diagnosed with Pseudotumor Cerebri. I went from being an Honor #39;s student at the University of Nebraska at Omaha, majoring in neuroscience and biotechnology (with a minor in chemistry) to be a disabled, frustrated neuro-patient with more doctors than I could manage. These conditions SUCK! And the hurt! And no one knows about them!!! My life now revolves around caring for my kiddos, helping fellow chiarians, and trying to tell the world about these horrid conditions. Of course I still do as much amature, non-laboratory based research in hopes of finding a way to return to my normal abnormal life. 🙂 A cure is there, we just have to find it.From:JohnnysAngel00Views:4 2ratingsTime:05:42More inScience Technology

Original post:
Neuroscience to Neuro-patient: Melissa's Chiari

The Money Report with Dave Gentry -E03- Biotechnology – Video

Posted on by


The Money Report with Dave Gentry -E03- Biotechnology
"The RedChip Money Report" delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies. The third episode features executive interviews with Galectin Therapeutics (NasdaqCM: GALT), ChromaDex Corp. (OTC BB: CDXC), NeoStem (NYSE: NBS), and Galena BioPharma (NasdaqCM: GALE). The show also features a segment on Echo Therapeutics (NasdaqCM: ECTE). Visit http://www.RedChip.com for more information.From:redchipuserViews:5 0ratingsTime:24:24More inNews Politics

See more here:
The Money Report with Dave Gentry -E03- Biotechnology - Video

Liberal (Mo.) gets Monsanto grant for biotechnology enhancement

Posted on by

Starting this fall, Liberal R-II School District will enhance current math and science programs with biotechnology. Thanks to the support of local farmers and Americas Farmers Grow Rural Education! , Liberal R-II School District received a $10,000 grant to buy lab equipment to perform advanced biotechnology, such as DNA fingerprinting and electrophoresis techniques. Students in biology, chemistry, anatomy, physiology and physical sciences classes will benefit from the grant.

Americas Farmers Grow Rural Education, sponsored by the Monsanto Fund, gives farmers the opportunity to nominate a public school district in their community to compete for a grant of either $10,000 or $25,000 to enhance education in the areas of math and/or science. More than 1,000 nominated school districts submitted applications. The Monsanto Fund will invest $2.3 million into rural education through this program.

Pam Clemensen, high school science teacher at Liberal High School, recalls how excited she was after hearing the news.

On the first day of school, Mr. Robertson, our high school principal, was welcoming our students back to school, introducing staff and going over the handbook, Clemensen said. Meanwhile, Mr. Harvey, our superintendent, walked into the gym and said I have some exciting news for you- Liberal received the Monsanto Grant! I was so excited! We just want to say thank you Monsanto, for providing this wonderful opportunity for our students.

After being nominated by local farmers, school districts completed an online application, and finalists were chosen by math and science teachers from ineligible school districts. The Americas Farmers Grow Rural Education Advisory Council, a group of 26 prominent farmers from across the country, then reviewed the finalists applications and selected the winners.

Local farmer James McClendon is one of the 48 farmers who nominated the Liberal R-II School District for the grant. McClendon is happy to see the school his grandson is currently attending receive funds to improve the ag education program.

We have less than 600 students enrolled in our schools and the town as a whole only has 700 people, McClendon said. We are an ag-based community, and its good that grants like this exist so that our children are exposed to the same opportunities as children in bigger school systems.

Link:
Liberal (Mo.) gets Monsanto grant for biotechnology enhancement

Pharma-Biotech Needs a New Financing Model or We Are Doomed! – Video

Posted on by


Pharma-Biotech Needs a New Financing Model or We Are Doomed!
Duane Roth, CEO, CONNECT Webinar Date: April 27, 2011 Agenda: » What killed the fully integrated model? » Has the start-up model run its course? » What will the next model look like? » Where will future investments come from? » What role should federal and state government play? Speaker Biography: Duane J. Roth is Chief Executive Officer and Member of the Board of CONNECT. CONNECT is the globally recognized nonprofit organization dedicated to creating and sustaining the growth of innovative technology and life science businesses in San Diego. CONNECT has been directly involved with over 2000 companies since its inception in 1985 and these companies have secured over $10 billion in funding. Prior to joining CONNECT, Mr. Roth founded Alliance Pharmaceutical Corp., where he served as Chairman of the Board. Prior to Alliance, he held senior management positions at Johnson Johnson and Wyeth (now Pfizer) operating companies. He has served as a Member of the Board of Directors and executive committees of the Biotechnology Industry Organization (BIO), the California Healthcare Institute (CHI) and BIOCOM (past Chair). Mr. Roth was appointed to the oversight board of the California Institute of Regenerative Medicine (CIRM) by Governor Arnold Schwarzenegger in 2006 and was elected Vice Chairman in 2009.From:ShareVaultViews:0 0ratingsTime:53:57More inEducation

Originally posted here:
Pharma-Biotech Needs a New Financing Model or We Are Doomed! - Video

Biotechnology Flourishes This Year With Investments Exceeding RM9 Billion

Posted on by

November 05, 2012 17:53 PM

Biotechnology Flourishes This Year With Investments Exceeding RM9 Billion

By Nor Baizura Basri

KUALA LUMPUR, Nov 5 (Bernama) -- Biotechnology sector has been flourishing this year despite facing various circumstantial "winds and bumps", with the industry surpassing the RM9 billion investment target for Phase 2, much earlier than targeted under the country's National Biotechnology Policy.

Malaysian Biotechnology Corporation Sdn Bhd (BiotechCorp) Chief Executive Officer Datuk Dr Mohd Nazlee Kamal said the industry, now in its commercialisation phase, has been progressing at a steady rate.

It has mobilised most of its potentials to ensure the transformation of the nation into a stable high-income nation by 2020, he said.

"The targeted investment for Phase 2 is RM9 billion. However, I am happy to say that we have indeed surpassed the investment target for Phase 2.

"Just for 2011 and and 2012, we've successfully attracted a total of RM12.72 billion in investments for the biotechnology industry," he told Bernama in an email interview in conjunction with the BioMalaysia 2012, which started Monday.

With the continuous market-based and pro-government support, Malaysia offered a dynamic and aggressive investment environment, especially under the National Biotechnology Policy, which has seen various tax and fiscal incentives to biotechnology companies, said Mohd Nazlee.

This was backed by the rich environmental biodiversity and a robust information and communications technology (ICT) infrastructure, enabling the country to be in a position to drive the country's biotechnology agenda and become one of the platforms for growth, he said.

See more here:
Biotechnology Flourishes This Year With Investments Exceeding RM9 Billion

Biotecb sector progressing at steady rate

Posted on by

KUALA LUMPUR: Biotechnology sector has been flourishing this year despite facing various circumstantial "winds and bumps", with the industry surpassing the RM9 million investment target for Phase 2, much earlier than targeted under the country's National Biotechnology Policy.

Malaysian Biotechnology Corporation Sdn Bhd (BiotechCorp) Chief Executive Officer Datuk Dr Mohd Nazlee Kamal said the industry, now in its commercialisation phase, has been progressing at a steady rate.

It has mobilised most of its potentials to ensure the transformation of the nation into a stable high-income nation by 2020, he said.

"The targeted investment for Phase 2 is RM9 billion. However, I am happy to say that we have indeed surpassed the investment target for Phase 2.

With the continuous market-based and pro-government support, Malaysia offered a dynamic and aggressive investment environment, especially under the National Biotechnology Policy, which has seen various tax and fiscal incentives to biotechnology companies, said Mohd Nazlee.

This was backed by the rich environmental biodiversity and a robust information and communications technology (ICT) infrastructure, enabling the country to be in a position to drive the countrys biotechnology agenda and become one of the platforms for growth, he said.

"In summary, Malaysia is the ideal investment destination for the biotechnology industry. Location-wise, we are in the middle of the rise of Asian markets and global companies which can optimise our country for businesses set in the Asia-Pacific.

"From the cost perspective, the price of liquefied petroleum gas, petrol, and diesel in Malaysia are among the cheapest in the world.

Utilisation of industrial electricity and water rates are competitive in the Southeast Asia region, he said.

Mohd Nazlee said that through the BioNexus status accorded to biotechnology companies that qualify under the Malaysian Bill of Guarantee, it would provide access to commercialisation and tax incentives.

See the rest here:
Biotecb sector progressing at steady rate

UK Government Awards £1.7M Grant to PsiOxus Therapeutics for Second Phase I/II Clinical Trial of Cancer Vaccine

Posted on by

OXFORD, England--(BUSINESS WIRE)--

PsiOxus Therapeutics, Ltd. (PsiOxus), a development stage biotechnology company, today announced the award of a 1.7 million ($2.7 million) grant from the UK government-backed Biomedical Catalyst to initiate a Phase I/II clinical trial to assess the use of ColoAd1 in the treatment of platinum-resistant, recurrent ovarian cancer. The OCTAVE (Ovarian Cancer Treated with AdenoVirus) study will be the second clinical trial of the systemically available oncolytic vaccine ColoAd1, which is a highly potent, broad-spectrum, anticancer therapeutic capable of destroying tumour cells at minute concentrations.

The OCTAVE Phase I/II study will assess the safety and efficacy of ColoAd1 when given to patients by intra-peritoneal perfusion at multiple UK cancer centres beginning in 2013. The Principal Investigator of the OCTAVE study will be Professor Iain McNeish from the Institute of Cancer Sciences at the University of Glasgow. Over 50 ovarian cancer patients will receive multiple doses of intra-peritoneal ColoAd1 in this clinical trial and will be assessed for immunological responses as well as tumor response and survival.

Ovarian cancer is the fourth most common cause of cancer death for women in the UK, said Iain McNeish, Professor of Gynecological Oncology at the University of Glasgow Institute of Cancer Sciences. This funding for the OCTAVE study will enable us to evaluate in great detail the use of ColoAd1 as a very exciting potential new treatment for ovarian cancer.

The grant is part of the 180 million Biomedical Catalyst, a programme of public funding designed to deliver growth to the UK life sciences sector. Operated jointly by the Medical Research Council and the Technology Strategy Board, it aims to provide responsive and effective support for the best life science opportunities that demonstrate the highest scientific and commercial potential.

We are delighted to be a recipient of this Biomedical Catalyst award in recognition of the important potential of our ColoAd1 oncolytic vaccine in addressing this global healthcare challenge. This form of matched funding is critical to help boost the UK life science sector and early stage biotechnology companies, such as PsiOxus, said Dr. John Beadle, CEO of PsiOxus Therapeutics. This grant enables PsiOxus to examine this exciting cancer vaccine in a second form of metastatic cancer, thus demonstrating its medical and commercial potential as a broad spectrum anti-cancer therapeutic.

ColoAd1 was developed using the evolutionary principle of natural selection to generate an oncolytic vaccine with optimal anti-cancer properties. The vaccine is injected into the bloodstream, and is then delivered to the cancer sites, where it replicates inside of cancer cells and kills them. Each infected cell produces thousands of new copies of ColoAd1, which spread to nearby cancer cells and kills them, as well, while ignoring normal cells. The approach represents a new generation of so-called self-amplifying cancer therapy that has the effect of killing tumors and acting as a cancer vaccine.

ColoAd1 is highly effective at selectively targeting and killing cancer cells while having little or no activity on normal tissue. ColoAd1 has been shown to be up to 1,200 times more potent at killing human cancer cells than non-cancerous human cells. Standard chemotherapy agents are much less selective for cancer cells, accounting for the often-severe side effects of chemotherapy. ColoAd1 is currently being investigated in the phase I/II Evolve (EValuating OncoLytic Vaccine Efficacy) clinical trial for the treatment of metastatic solid tumours. The first three patients have so far been dosed, with initial results of this phase I component of the study expected by the end of 2013.

About PsiOxus Therapeutics, Ltd.

PsiOxus Therapeutics is an Oxford, UK-based development stage biotechnology company using non-traditional approaches to develop novel therapeutics that address cancer and other clinically unmet diseases. ColoAd1 is an oncolytic vaccine for the systemic treatment of metastatic cancer, which has demonstrated exceptional anti-cancer properties in late pre-clinical development and is now in phase I clinical development. MT-102 is a dual action Anabolic Catabolic Transforming Agent (ACTA) in phase II clinical development for the treatment of cachexia and sarcopenia. The Company is also developing treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines.

Here is the original post:
UK Government Awards £1.7M Grant to PsiOxus Therapeutics for Second Phase I/II Clinical Trial of Cancer Vaccine

2012 Drought: Reflecting on the Good – Video

Posted on by


2012 Drought: Reflecting on the Good
http://www.csdigest.com After the worst drought in the US since the Dust Bowl, it #39;s time to look back and find some positives. Kent Thiesse, vice president, MinnStar Bank, Lake Crystal, Minn., and former Extension educator, acknowles that while there were many hard-hit areas, Thiesse also points out that yields may have been surprising in a good way thanks to biotechnology improvements, improved tillage management and soil conservation.From:CornSoybeanDigestViews:1 0ratingsTime:02:53More inScience Technology

See the original post here:
2012 Drought: Reflecting on the Good - Video

Watch Ted Kennedy: Historic Speech @ Denver Convention – Ted Kennedy – Video

Posted on by


Watch Ted Kennedy: Historic Speech @ Denver Convention - Ted Kennedy
Watch full movie here : free-hot-movies.com Kennedy Ted supreme court health vote vicki kennedy health care Ted Kennedy Rep Ron Paul Personal Liberty Alerts Mitt Romney (TV Actor) health reform vote health care reform obama health care Senator does not agree mary jo kopechne Wayne Allyn Root mitt romney bain Massachusetts senator kennedy Healthcare bain commercial 2008Conventions edward kennedy robert kennedy Bob Livingston Romney convention2008 chappaquiddick supreme court health reform life sciences Onion Network devine mulvey biotechnology massachusetts john kennedy bain capital assasination bigthink.com plane crash Edward Speech republicans Romney 1994 Wayne Root worker ads tad devine Travaglini romneycare Foundation Individual individual democrats Signing Tribute Mitt care The Onion Big Think bob shrum obamacare Nation The the bain ads Ceremony Heritage politics Congress bigthink democrat Obama workers biotech Moffitt Mandate mandate Network western senator Sen. 2006 News DNC denver Boston shrugs pamela geller SCOTUS senate edward dimasi Robert pelosi health heaven comedy satire obama for ted kennedy health care GlobeFrom:MichalBlumenkrantzViews:0 0ratingsTime:09:51More inFilm Animation

Read more here:
Watch Ted Kennedy: Historic Speech @ Denver Convention - Ted Kennedy - Video

What is NeriumAD Safety – Video

Posted on by


What is NeriumAD Safety
A premier anti-aging company committed to providing quality skin care products. Its unique REAL science addresses aging at its source. http://www.skincoinc.com At the recently held North American Congress of Clinical Toxicology (NACCT) meeting in Las Vegas, Dennis Knocke, CEO of Nerium Biotechnology, exhibited and shared product safety information about Nerium AD Age-Defying Treatment and provided product samples to the attending MDs, PhDs, Phar.Ds., FDA representatives, FBI Toxicologists and Poison Control Center Directors http://www.facebook.com http://www.twitter.comFrom:skincoincViews:0 0ratingsTime:11:02More inHowto Style

Go here to read the rest:
What is NeriumAD Safety - Video

1000 Genomes Project – Defining Genetic Variation in People – Video

Posted on by


1000 Genomes Project - Defining Genetic Variation in People
An international team of researchers working on the 1000 Genomes Project published in Nature on Nov. 1, 2012, interim findings on the first 1092 people to have their genomes sequenced. Four leaders in the project discuss the results in this new video from NHGRI #39;s Genome Projections: Lisa Brooks, National Human Genome Research Institute Stephen T. Sherry, Ph.D., National Center for Biotechnology Information Gilean McVean, Ph.D., University of Oxford David Altshuler, MD, Ph.D., The Broad Institute of MIT and HarvardFrom:GenomeTVViews:3 7ratingsTime:11:23More inScience Technology

More here:
1000 Genomes Project - Defining Genetic Variation in People - Video

The Dark Side of the Double Helix: Andrew Hessel at TEDx Marin 2012 – Video

Posted on by


The Dark Side of the Double Helix: Andrew Hessel at TEDx Marin 2012
A fascinating inside look at the coming world of Synthetic Biology. Andrew Hessel is a futurist and catalyst in biological technologies, helping industry, academics, and authorities better understand the changes underway in life science. Trained in microbiology and genetics, Andrew has continually worked at the forefront of life science in industry and academia. He is faculty at Singularity University, where he co-chaired the Biotechnology and Bioinformatics track and now helps startup biotechnology companies organize and launch. He is also a fellow at the University of Ottawa, Institute for Science, Society, and Policy, and the founder of the world #39;s first cooperative biotechnology company, the Pink Army Cooperative, which is working to create open source therapies for cancer. Andrew has given dozens of invited talks related to synthetic biology, for groups that include Intel Inc., the FBI, and the United Nations. In thespirit of ideas worth spreading, TEDx is a program of local, self-organized events that bring people together to share a TED-like experience. At a TEDx event, TEDTalks video and live speakers combine to spark deep discussion and connection in a small group. These local, self-organized events are branded TEDx, where x = independently organized TED event. The TED Conference provides general guidance for the TEDx program, but individual TEDx events are self-organized.* (*Subject to certain rules and regulations)From:TEDxTalksViews:65 11ratingsTime:19:05More inScience Technology

See more here:
The Dark Side of the Double Helix: Andrew Hessel at TEDx Marin 2012 - Video

Dendritic Cells: Biology And Clinical Applications – Video

Posted on by


Dendritic Cells: Biology And Clinical Applications
ll4.me Dendritic Cells: Biology And Clinical Applications Dendritic Cells, 2nd Edition is the new edition of the extremely successful book published in 1998. With the volume of literature on dendritic cells doubling every year, it is almost impossible to keep up. This book provides the most up-to-date synthesis of the literature, written by the very best authors. It is essential reading for any scientist working in immunology, cell biology, infectious diseases, cancer, transplantation, genetic engineering, or the pharmaceutical/biotechnology industry.* An entirely new section on DC biology is included in this edition. Also new to this edition are chapters on:* Imaging* Interaction of dendritic cells with viruses* Dendritic cells and dendrikines, chemokines and the endothelium* Molecules expressed in dendritic cells* Role of dendritic cells in wound healing and atherosclerosis* Delivery of apoptotic bodies* Genetic engineering of dendritic cells* Imaging* Practical aspects of clinical protocol development Publisher: Academic Press Illustration: N Language: ENG Title: Dendritic Cells: Biology and Clinical Applications Pages: 00000 (Encrypted PDF) On Sale: 2001-10-08 SKU-13/ISBN: 9780124558519 Category: Medical : Immunology Category: Science : Life Sciences - Microbiology Category: Science : Life Sciences - Cell Biology Dendritic Cells, 2nd Edition is the new edition of the extremely successful book published in 1998. With the volume of literature on dendritic cells doubling ...From:briannielsen658Views:0 0ratingsTime:00:11More inPeople Blogs

See the rest here:
Dendritic Cells: Biology And Clinical Applications - Video